AUR-103 / Dr. Reddy’s, Aurigene - LARVOL DELTA

AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study) (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P2 trial • Neuroendocrine Tumor • Oncology • Solid Tumor

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=2 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=18 ➔ 2 | Trial completion date: Nov 2028 ➔ Dec 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2027 ➔ Dec 2025; Patient recruitment problems.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=27 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=80 ➔ 27 | Recruiting ➔ Terminated; Patient recruitment problems.

Enrollment change • First-in-human • Trial termination • Acute Myelogenous Leukemia • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Marginal Zone Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Solid Tumor

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P1/2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES (EHA 2023) - P1 | "Subsequent to determining the OBD of single agent AUR103, combination studies with azacitidine and/or azacitidine/Venetoclax and/or ADCC competent antibodies will be studied in relevant tumor types. AUR103 is a novel First in Class small molecule inhibitor of CD47. The First in Human trial (AUR103-101; BHARAT) is currently enrolling. The preliminary safety in the first two cohorts appears commensurate with "lack of haemolysis" in non-clinical models."

Clinical • Metastases • P1 data • Acute Myelogenous Leukemia • Anemia • Anorexia • Hematological Disorders • Musculoskeletal Pain • Oncology • Pain • Pruritus • CD47 • SIRPA

BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P1 trial • Acute Myelogenous Leukemia • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor